XML 52 R14.htm IDEA: XBRL DOCUMENT
v3.25.2

Financial Instruments | 12 Months Ended
--- | ---
Apr. 25, 2025
Investments [Abstract] |
Financial Instruments | Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at April 25, 2025 and April 26, 2024:
| April 25, 2025
| Valuation |  | Balance Sheet Classification
(in millions) | Cost |  | Unrealized Gains |  | Unrealized Losses |  | Fair Value |  | Investments |  | Other Assets
Level 1: |  |  |  |  |  |  |  |  |  |  |
U.S. government and agency securities | $ | 417 |  |  | $ | — |  |  | $ | (7) |  |  | $ | 410 |  |  | $ | 410 |  |  | $ | — |
Level 2: |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities | 3,540 |  |  | 17 |  |  | (36) |  |  | 3,521 |  |  | 3,521 |  |  | — |
U.S. government and agency securities | 835 |  |  | — |  |  | (20) |  |  | 814 |  |  | 814 |  |  | — |
Mortgage-backed securities | 948 |  |  | 4 |  |  | (29) |  |  | 923 |  |  | 923 |  |  | — |
Non-U.S. government and agency securities | 6 |  |  | — |  |  | — |  |  | 6 |  |  | 6 |  |  | — |
Other asset-backed securities | 1,044 |  |  | 5 |  |  | (6) |  |  | 1,044 |  |  | 1,044 |  |  | — |
Total Level 2 | 6,373 |  |  | 26 |  |  | (91) |  |  | 6,308 |  |  | 6,308 |  |  | — |
Level 3: |  |  |  |  |  |  |  |  |  |  |
Auction rate securities | 36 |  |  | — |  |  | (3) |  |  | 33 |  |  | — |  |  | 33 |
Total available-for-sale debt securities | $ | 6,826 |  |  | $ | 26 |  |  | $ | (100) |  |  | $ | 6,752 |  |  | $ | 6,719 |  |  | $ | 33 |
| April 26, 2024
| Valuation |  | Balance Sheet Classification
(in millions) | Cost |  | Unrealized Gains |  | Unrealized Losses |  | Fair Value |  | Investments |  | Other Assets
Level 1: |  |  |  |  |  |  |  |  |  |  |
U.S. government and agency securities | $ | 494 |  |  | $ | — |  |  | $ | (22) |  |  | $ | 472 |  |  | $ | 472 |  |  | $ | — |
Level 2: |  |  |  |  |  |  |  |  |  |  |
Corporate debt securities | 3,953 |  |  | 4 |  |  | (125) |  |  | 3,832 |  |  | 3,832 |  |  | — |
U.S. government and agency securities | 847 |  |  | — |  |  | (43) |  |  | 804 |  |  | 804 |  |  | — |
Mortgage-backed securities | 692 |  |  | 1 |  |  | (50) |  |  | 643 |  |  | 643 |  |  | — |
Non-U.S. government and agency securities | 5 |  |  | — |  |  | — |  |  | 5 |  |  | 5 |  |  | — |
Other asset-backed securities | 941 |  |  | 2 |  |  | (9) |  |  | 934 |  |  | 934 |  |  | — |
Total Level 2 | 6,438 |  |  | 7 |  |  | (227) |  |  | 6,218 |  |  | 6,218 |  |  | — |
Level 3: |  |  |  |  |  |  |  |  |  |  |
Auction rate securities | 36 |  |  | — |  |  | (3) |  |  | 33 |  |  | — |  |  | 33 |
Total available-for-sale debt securities | $ | 6,968 |  |  | $ | 7 |  |  | $ | (252) |  |  | $ | 6,723 |  |  | $ | 6,690 |  |  | $ | 33 |
The amortized cost of debt securities excludes accrued interest, which is reported in other current assets in the consolidated balance sheets. The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale debt securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at April 25, 2025 and April 26, 2024:
| April 25, 2025
| Less than 12 months |  | More than 12 months
(in millions) | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses
Corporate debt securities | $ | 702 |  |  | $ | (7) |  |  | $ | 1,235 |  |  | $ | (29) |
U.S. government and agency securities | 110 |  |  | (1) |  |  | 641 |  |  | (25) |
Mortgage-backed securities | 2 |  |  | (1) |  |  | 614 |  |  | (28) |
Other asset-backed securities | — |  |  | — |  |  | 469 |  |  | (6) |
Auction rate securities | — |  |  | — |  |  | 33 |  |  | (3) |
Total | $ | 814 |  |  | $ | (9) |  |  | $ | 2,993 |  |  | $ | (91) |
| April 26, 2024
| Less than 12 months |  | More than 12 months
(in millions) | Fair Value |  | Unrealized Losses |  | Fair Value |  | Unrealized Losses
Corporate debt securities | $ | 661 |  |  | $ | (10) |  |  | $ | 2,448 |  |  | $ | (116) |
U.S. government and agency securities | 177 |  |  | (4) |  |  | 730 |  |  | (61) |
Mortgage-backed securities | — |  |  | — |  |  | 582 |  |  | (50) |
Other asset-backed securities | — |  |  | — |  |  | 502 |  |  | (9) |
Auction rate securities | — |  |  | — |  |  | 33 |  |  | (3) |
Total | $ | 838 |  |  | $ | (14) |  |  | $ | 4,296 |  |  | $ | (238) |
The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. There were no transfers into or out of Level 3 during the fiscal years ended April 25, 2025 and April 26, 2024. When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The table below includes activity related to the Company’s available-for-sale debt securities portfolio. Gains and losses on available-for-sale debt securities are recognized in other non-operating income, net in the consolidated statements of income.
| Fiscal Year
(in millions) | 2025 |  | 2024 |  | 2023
Proceeds from sales | $ | 8,213 |  |  | $ | 7,359 |  |  | $ | 7,321 |
Gross realized gains | 25 |  |  | 24 |  |  | 10 |
Gross realized losses | (19) |  |  | (26) |  |  | (43) |
The contractual maturities of available-for-sale debt securities at April 25, 2025 are shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties.
(in millions) | Amortized Cost |  | Fair Value
Due in one year or less | $ | 1,458 |  |  | $ | 1,448 |
Due after one year through five years | 3,183 |  |  | 3,149 |
Due after five years through ten years | 845 |  |  | 843 |
Due after ten years | 1,340 |  |  | 1,313 |
Total | $ | 6,826 |  |  | $ | 6,752 |
Interest income, which includes income on marketable debt securities and the global liquidity structures, is recognized in other non-operating income, net, in the consolidated statements of income. For fiscal years 2025, 2024, and 2023 there was $511 million, $597 million, and $386 million of interest income, respectively. Equity Securities, Equity Method Investments, and Other Investments The following table summarizes the Company's equity and other investments at April 25, 2025 and April 26, 2024, which are classified as primarily other assets in the consolidated balance sheets:
(in millions) |  | April 25, 2025 |  | April 26, 2024
Investments with readily determinable fair value (marketable equity securities) |  | $ | 17 |  |  | $ | 28 |
Investments for which the fair value option has been elected |  | 140 |  |  | 311 |
Investments without readily determinable fair values |  | 705 |  |  | 859 |
Equity method and other investments |  | 89 |  |  | 84 |
Total equity and other investments |  | $ | 951 |  |  | $ | 1,282 |
The table below includes activity related to the Company's portfolio of equity and other investments. The activity for fiscal years 2024 and 2023 was not significant. Gains and losses on equity and other investments are recognized in other non-operating income, net in the consolidated statements of income.
| Fiscal Year |  |  |  |
(in millions) | 2025 |  |  |  |
Proceeds from sales | $ | 308 |  |  |  |  |
Gross gains | 108 |  |  |  |  |
Gross losses | (204) |  |  |  |  |
Impairment losses recognized | (135) |  |  |  |  |
During fiscal year 2025, there were $181 million of net unrealized losses on equity securities and other investments still held at April 25, 2025. During fiscal year 2024, there were $291 million of net unrealized losses on equity securities and other investments still held at April 26, 2024. Mozarc Medical Investment As further described in Note 3, on April 1, 2023 the Company sold half of its RCS business to Mozarc, and as a result of the transaction the Company retained a 50% equity interest in Mozarc. Although the equity investment provides the Company with the ability to exercise significant influence over Mozarc, the Company has elected the fair value option to account for this equity investment. The Company believes the fair value option best reflects the economics of the underlying transaction. Under the fair value option, changes in the fair value of the investment are recognized through earnings each reporting period in other non-operating income, net in the consolidated statements of income. During fiscal year 2025 and 2024, the Company recognized a loss of $171 million and $220 million, respectively, primarily driven by the timing of anticipated product launches, historical financial results, and projections of future cash flows. The following table provides a reconciliation of the beginning and ending balances of the Mozarc investment for which the fair value option has been elected:
| Fiscal Year
(in millions) | 2025 |  | 2024
Beginning Balance | $ | 311 |  |  | $ | 531 |
Change in fair value | (171) |  |  | (220) |
Ending Balance | $ | 140 |  |  | $ | 311 |

X
- Definition The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures. + References No definition available. + Details
Name: | us-gaap_FinancialInstrumentsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration